Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia

Inclusion Criteria:

Patients with recurrent or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Prior treatment with at least 2 systemic chemotherapy regimens for CLL
Life expectancy of >3 months
Adequate liver and kidney function
Absolute neutrophil count ≥500/mm3; platelets ≥50,000/dL; hemoglobin ≥9 g/dL
Willing to use accepted method of contraception during the course of the study
Negative pregnancy test (females)
Written informed consent

Exclusion Criteria:

Chemotherapy or radiotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
Investigational drug within 30 days of the start of treatment
Uncontrolled intercurrent illness such as infection or cardiovascular disease
Pregnant or breastfeeding women
Subjects known to be HIV positive